Motus GI Holdings 미래 성장

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Motus GI Holdings 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

OTCPK:MOTS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	0	-16	-8	-8	N/A
12/31/2023	0	-13	-11	-11	N/A
9/30/2023	0	-14	-13	-13	N/A
6/30/2023	1	-16	-15	-15	N/A
3/31/2023	1	-18	-17	-17	N/A
12/31/2022	1	-19	-18	-17	N/A
9/30/2022	1	-20	-18	-17	N/A
6/30/2022	0	-20	-17	-17	N/A
3/31/2022	0	-19	-15	-15	N/A
12/31/2021	0	-25	-15	-14	N/A
9/30/2021	0	-25	-14	-13	N/A
6/30/2021	0	-24	-13	-13	N/A
3/31/2021	0	-24	-15	-14	N/A
12/31/2020	0	-19	-17	-17	N/A
9/30/2020	0	-21	-20	-20	N/A
6/30/2020	0	-22	-22	-21	N/A
3/31/2020	0	-23	-22	-22	N/A
12/31/2019	0	-23	-20	-20	N/A
9/30/2019	0	-23	-20	-19	N/A
6/30/2019	0	-23	-18	-17	N/A
3/31/2019	0	-21	-18	-17	N/A
12/31/2018	0	-22	-15	-15	N/A
9/30/2018	0	-20	-14	-13	N/A
6/30/2018	0	-18	-13	-13	N/A
3/31/2018	0	-18	-12	-12	N/A
12/31/2017	N/A	-13	N/A	-10	N/A
9/30/2017	N/A	-12	N/A	-10	N/A
6/30/2017	N/A	-11	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-7	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

애널리스트 미래 성장 예측

수입 대 저축률: MOTS 의 예상 수익 증가율이 절약률( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: MOTS 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: MOTS 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: MOTS 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: MOTS 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MOTS 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Motus GI Holdings 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates upgraded to US$24.75 loss, revenue downgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus EPS estimates upgraded to US$2.48 loss

Price target increased by 58% to US$10.00

Consensus revenue estimates fall by 22%

Price target decreased to US$11.00

Recent updates

Motus GI Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $4.99972 million.

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Consensus EPS estimates upgraded to US$24.75 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

New minor risk - Share price stability

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Consensus EPS estimates upgraded to US$2.48 loss

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

Price target increased by 58% to US$10.00

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Consensus revenue estimates fall by 22%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI regains compliance with minimum bid price requirement

Motus GI Holdings announces 1-for-20 reverse stock split to satisfy Nasdaq's minimum bid requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

Price target decreased to US$1.43

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Price target decreased to US$1.73

Consensus EPS estimates fall by 13%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Price target decreased to US$1.86

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Consensus forecasts updated

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

Motus GI starts enrollment in Pure-Vu System EU study

Consensus forecasts updated

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Price target decreased to US$2.24

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Motus GI shares rocket 55% on FDA 510(k) clearance of Pure-Vu System